{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:55:14Z","timestamp":1792684514478,"version":"4.5.0"},"reference-count":49,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.3201\/eid3104.241820","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:55:59Z","timestamp":1741870559000},"source":"Crossref","is-referenced-by-count":21,"title":["Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023\u20132024"],"prefix":"10.3201","volume":"31","author":[{"given":"Philippe Noriel Q.","family":"Pascua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Chesnokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan De","family":"La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunho","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei A.","family":"Ivashchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre V.","family":"Ivachtchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borann","family":"Sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Savuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Uyeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Todd","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa V.","family":"Gubareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3104.241820-202503130853-R1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2414610","article-title":"Highly pathogenic avian influenza a(h5n1) virus infections in humans.","volume":"392","author":"Garg","year":"2025","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3201\/eid2805.220318","article-title":"Intercontinental movement of highly pathogenic avian influenza A(H5N1) clade 2.3.4.4 virus to the United States, 2021.","volume":"28","author":"Bevins","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R3","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.3201\/eid2912.230464","article-title":"Highly pathogenic avian influenza A(H5N1) virus clade 2.3.4.4b infections in wild terrestrial mammals, United States, 2022.","volume":"29","author":"Elsmo","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R4","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1038\/s41467-023-41182-0","article-title":"Highly pathogenic avian influenza A (H5N1) in marine mammals and seabirds in Peru.","volume":"14","author":"Leguia","year":"2023","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid3104.241820-202503130853-R5","doi-asserted-by":"publisher","first-page":"109860","DOI":"10.1016\/j.virol.2023.109860","article-title":"H5N1 highly pathogenic avian influenza clade 2.3.4.4b in wild and domestic birds: Introductions into the United States and reassortments, December 2021-April 2022.","volume":"587","author":"Youk","year":"2023","journal-title":"Virology"},{"key":"key-10.3201\/eid3104.241820-202503130853-R6","doi-asserted-by":"publisher","first-page":"taad032","DOI":"10.1093\/jtm\/taad032","article-title":"First case of human infection with highly pathogenic H5 avian Influenza A virus in South America: A new zoonotic pandemic threat for 2023?","volume":"30","author":"Bruno","year":"2023","journal-title":"J Travel Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R7","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral drug resistance. 2022 [cited 2024 Sep 30]. https:\/\/www.cdc.gov\/flu\/treatment\/antiviralresistance.html"},{"key":"key-10.3201\/eid3104.241820-202503130853-R8","doi-asserted-by":"publisher","first-page":"taad083","DOI":"10.1093\/jtm\/taad083","article-title":"The first case of human infection with H5N1 avian Influenza A virus in Chile.","volume":"30","author":"Castillo","year":"2023","journal-title":"J Travel Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R9","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3201\/eid3007.240508","article-title":"Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus infection in domestic dairy cattle and cats, United States, 2024.","volume":"30","author":"Burrough","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R10","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMc2405371","article-title":"Highly pathogenic avian influenza A(H5N1) virus infection in a dairy farm worker.","volume":"390","author":"Uyeki","year":"2024","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1056\/NEJMc2407264","article-title":"Influenza A(H5N1) virus infection in two dairy farm workers in Michigan.","volume":"391","author":"Morse","year":"2024","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm7334a1","article-title":"H5N1 Field Investigation Team. Cluster of influenza A(H5) cases associated with poultry exposure at two facilities\u2014Colorado, July 2024.","volume":"73","author":"Drehoff","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.3201\/eid3104.241820-202503130853-R13","unstructured":"Centers for Disease Control and Prevention. CDC confirms new human cases of H5 bird flu in California. 2024 Oct 3 [cited 2024 Oct 3]. https:\/\/www.cdc.gov\/media\/releases\/2024\/s1003-birdflu-case-california.html"},{"key":"key-10.3201\/eid3104.241820-202503130853-R14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/82_2014_419","article-title":"Pandemic preparedness and the influenza risk assessment tool (IRAT).","volume":"385","author":"Cox","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"key-10.3201\/eid3104.241820-202503130853-R15","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.lanmic.2024.100973","article-title":"Pandemic risk characterisation of zoonotic influenza A\u00a0viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA).","volume":"6","author":"Yamaji","year":"2025","journal-title":"Lancet Microbe"},{"key":"key-10.3201\/eid3104.241820-202503130853-R16","doi-asserted-by":"publisher","first-page":"105499","DOI":"10.1016\/j.antiviral.2022.105499","article-title":"Influenza antivirals and their role in pandemic preparedness.","volume":"210","author":"Jones","year":"2023","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R17","doi-asserted-by":"publisher","first-page":"430629","DOI":"10.1155\/2014\/430629","article-title":"A review of the antiviral susceptibility of human and avian influenza viruses over the last decade.","volume":"2014","author":"Oh","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"key-10.3201\/eid3104.241820-202503130853-R18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.antiviral.2015.02.004","article-title":"Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.","volume":"117","author":"Baranovich","year":"2015","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R19","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1086\/504723","article-title":"Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.","volume":"193","author":"Cheung","year":"2006","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R20","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral drug resistance. 2022 [cited 2025 Jan 3]. https:\/\/www.cdc.gov\/flu\/treatment\/antiviralresistance.html"},{"key":"key-10.3201\/eid3104.241820-202503130853-R21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses.","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"key-10.3201\/eid3104.241820-202503130853-R22","doi-asserted-by":"publisher","first-page":"105679","DOI":"10.1016\/j.antiviral.2023.105679","article-title":"Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022.","volume":"217","author":"Nguyen","year":"2023","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R23","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.antiviral.2022.105281","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020.","volume":"200","author":"Govorkova","year":"2022","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R24","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/jac\/dku074","article-title":"Novel oral anti-influenza drug candidate AV5080.","volume":"69","author":"Ivachtchenko","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid3104.241820-202503130853-R25","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza A, B, C, and D viruses to baloxavir.","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R26","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/jac\/dkaa524","article-title":"Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.","volume":"76","author":"Ivashchenko","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid3104.241820-202503130853-R27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3104.241820-202503130853-R28","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/infdis\/jiad418","article-title":"Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses circulating globally in 2022\u20132023.","volume":"229","author":"Andreev","year":"2024","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R29","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12864-016-3030-6","article-title":"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler.","volume":"17","author":"Shepard","year":"2016","journal-title":"BMC Genomics"},{"key":"key-10.3201\/eid3104.241820-202503130853-R30","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability.","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol Biol Evol"},{"key":"key-10.3201\/eid3104.241820-202503130853-R31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3851\/IMP1678","article-title":"Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.","volume":"15","author":"Gubareva","year":"2010","journal-title":"Antivir Ther"},{"key":"key-10.3201\/eid3104.241820-202503130853-R32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.antiviral.2016.01.009","article-title":"Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.","volume":"128","author":"Okomo-Adhiambo","year":"2016","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R33","doi-asserted-by":"publisher","first-page":"105457","DOI":"10.1016\/j.antiviral.2022.105457","article-title":"An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance.","volume":"208","author":"Patel","year":"2022","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R34","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.","volume":"321","author":"Hayden","year":"1989","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3104.241820-202503130853-R35","doi-asserted-by":"publisher","first-page":"105035","DOI":"10.1016\/j.antiviral.2021.105035","article-title":"Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir.","volume":"188","author":"Patel","year":"2021","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir Ther"},{"key":"key-10.3201\/eid3104.241820-202503130853-R37","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11262-019-01700-z","article-title":"Inventory of molecular markers affecting biological characteristics of avian influenza A viruses.","volume":"55","author":"Suttie","year":"2019","journal-title":"Virus Genes"},{"key":"key-10.3201\/eid3104.241820-202503130853-R38","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1099\/jgv.0.000770","article-title":"Enhanced pathogenicity and neurotropism of mouse-adapted H10N7 influenza virus are mediated by novel PB2 and NA mutations.","volume":"98","author":"Zhang","year":"2017","journal-title":"J Gen Virol"},{"key":"key-10.3201\/eid3104.241820-202503130853-R39","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1128\/AAC.01667-08","article-title":"Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.","volume":"53","author":"Govorkova","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3104.241820-202503130853-R40","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3201\/eid1309.070164","article-title":"Reduced sensitivity of influenza A (H5N1) to oseltamivir.","volume":"13","author":"McKimm-Breschkin","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3104.241820-202503130853-R41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2018.03.007","article-title":"Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.","volume":"153","author":"McKimm-Breschkin","year":"2018","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R42","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1128\/AAC.00645-06","article-title":"Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.","volume":"50","author":"Rameix-Welti","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid3104.241820-202503130853-R43","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"key-10.3201\/eid3104.241820-202503130853-R44","doi-asserted-by":"publisher","first-page":"105959","DOI":"10.1016\/j.antiviral.2024.105959","article-title":"Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.","volume":"229","author":"Andreev","year":"2024","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid3104.241820-202503130853-R45","doi-asserted-by":"crossref","unstructured":"van der Vries E, Ison MG. Antiviral resistance in influenza viruses: clinical and epidemiological aspects. In: Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D, editors. Antimicrobial Drug Resistance. Springer Cham; 2017. p. 1165\u201383.","DOI":"10.1007\/978-3-319-47266-9_23"},{"key":"key-10.3201\/eid3104.241820-202503130853-R46","doi-asserted-by":"publisher","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice.","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid3104.241820-202503130853-R47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/v14010111","article-title":"Characterization of the in vitro and in vivo efficacy of baloxavir marboxil against H5 highly pathogenic avian influenza virus infection.","volume":"14","author":"Taniguchi","year":"2022","journal-title":"Viruses"},{"key":"key-10.3201\/eid3104.241820-202503130853-R48","unstructured":"Centers for Disease Control and Prevention. 2024. Interim guidance on the use of antiviral medications for treatment of human infections with novel influenza A viruses associated with severe human disease. [cited 2024 Sep 30]. https:\/\/www.cdc.gov\/bird-flu\/hcp\/novel-av-treatment-guidance"},{"key":"key-10.3201\/eid3104.241820-202503130853-R49","unstructured":"Centers for Disease Control and Prevention. 2024. Interim guidance for follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease or with potential to cause severe human disease, and use of antiviral medications for post-exposure prophylaxis [cited 2024 Sep 30]. https:\/\/www.cdc.gov\/bird-flu\/php\/novel-av-chemoprophylaxis-guidance"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:56:04Z","timestamp":1741870564000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/4\/24-1820_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3104.241820","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}